Duvuru Geetha

Dr. Duvuru Geetha


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2021 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
CCCaoilfhionn M. Connolly
Caoilfhionn M. Connolly
JRJake A. Ruddy
Jake A. Ruddy
BBBrian J. Boyarsky
Brian J. Boyarsky
IBIulia Barbur
Iulia Barbur
WWWilliam A. Werbel
William A. Werbel
JPJulie J. Paik
Julie J. Paik
Objective: To evaluate disease flare and postvaccination reactions (reactogenicity) in patients with rheumatic and musculoskeletal diseases (RMDs) following 2‐dose SARS–CoV‐2 messenger RNA (mRNA) vaccination.Methods: RMD patients (n = 1,377) who received 2‐dose SARS–CoV‐2 mRNA vaccination between December 16, 2020 and April 15, 2021 completed questionnaires detailing local and systemic reactions experienced within 7 days of each vaccine dose (dose 1 and dose 2), and 1 month after dose 2, detailing any flares of RMD. Associations between demographic/clinical characteristics and flares requiring treatment were evaluated using modified Poisson regression.Results: Among the patients, 11% reported flares requiring treatment; there were no reports of severe flares. Flares were associated with prior SARS–CoV‐2 infection (incidence rate ratio [IRR] 2.09, P = 0.02), flares in the 6 months preceding vaccination (IRR 2.36, P < 0.001), and the use of combination immunomodulatory therapy (IRR 1.95, P < 0.001). The most frequently reported local and systemic reactions included injection site pain (87% after dose 1, 86% after dose 2) and fatigue (60% after dose 1, 80% after dose 2). Reactogenicity increased after dose 2, particularly for systemic reactions. No allergic reactions or SARS–CoV‐2 diagnoses were reported.Conclusion: Flares of underlying RMD following SARS–CoV‐2 vaccination were uncommon. There were no reports of severe flares. Local and systemic reactions typically did not interfere with daily activity. These early safety data can help address vaccine hesitancy in RMD patients.

12 December 2023 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
SBSebastian Bate
Sebastian Bate
DMDominic McGovern
Dominic McGovern
FCFrancesca Costigliolo
Francesca Costigliolo
PTPek Ghe Tan
Pek Ghe Tan
VKVojtech Kratky
Vojtech Kratky
SBSilke R. Brix
Silke R. Brix
Significance Statement: Reliable prediction tools are needed to personalize treatment in ANCA-associated GN. More than 1500 patients were collated in an international longitudinal study to revise the ANCA kidney risk score. The score showed satisfactory performance, mimicking the original study (Harrell's C=0.779). In the development cohort of 959 patients, no additional parameters aiding the tool were detected, but replacing the GFR with creatinine identified an additional cutoff. The parameter interstitial fibrosis and tubular atrophy was modified to allow wider access, risk points were reweighted, and a fourth risk group was created, improving predictive ability (C=0.831). In the validation, the new model performed similarly well with excellent calibration and discrimination (n=480, C=0.821). The revised score optimizes prognostication for clinical practice and trials. Background: Reliable prediction tools are needed to personalize treatment in ANCA-associated GN. A retrospective international longitudinal cohort was collated to revise the ANCA renal risk score. Methods: The primary end point was ESKD with patients censored at last follow-up. Cox proportional hazards were used to reweight risk factors. Kaplan–Meier curves, Harrell's C statistic, receiver operating characteristics, and calibration plots were used to assess model performance. Results: Of 1591 patients, 1439 were included in the final analyses, 2:1 randomly allocated per center to development and validation cohorts (52% male, median age 64 years). In the development cohort (n=959), the ANCA renal risk score was validated and calibrated, and parameters were reinvestigated modifying interstitial fibrosis and tubular atrophy allowing semiquantitative reporting. An additional cutoff for kidney function (K) was identified, and serum creatinine replaced GFR (K0: 450 µmol/L=11 points). The risk points for the percentage of normal glomeruli (N) and interstitial fibrosis and tubular atrophy (T) were reweighted (N0: >25%=0, N1: 10%–25%=4, N2: <10%=7, T0: none/mild or <25%=0, T1: ≥ mild-moderate or ≥25%=3 points), and four risk groups created: low (0–4 points), moderate (5–11), high (12–18), and very high (21). Discrimination was C=0.831, and the 3-year kidney survival was 96%, 79%, 54%, and 19%, respectively. The revised score performed similarly well in the validation cohort with excellent calibration and discrimination (n=480, C=0.821). Conclusions: The updated score optimizes clinicopathologic prognostication for clinical practice and trials.

24 August 2022 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
DGDuvuru Geetha
Duvuru Geetha
Andreas KronbichlerAndreas Kronbichler
Andreas Kronbichler
MRMegan Rutter
Megan Rutter
DBDivya Bajpai
Divya Bajpai
SMSteven Menez
Steven Menez
VLValerie Luyckx
Valerie Luyckx

2 November 2018 in Journal of Community Hospital Internal Medicine Perspectives
Verified
Journal Article
Open access
QJQiuyu Jin
Qiuyu Jin
SKSam Kant
Sam Kant
JAJihad Alhariri
Jihad Alhariri
DGDuvuru Geetha
Duvuru Geetha
Levamisole is an antihelminth drug and a common cocaine contaminant, present in an estimated 71% of cocaine samples in the US. Levamisole-contaminated cocaine has been linked to an ANCA-associated vasculitis with cutaneous, renal, and pulmonary manifestations. We report the case of a 46 year old woman with known cocaine exposure who presents with recurrent, large purpuric and maculopapular rash of the extremities and face and review existing cases of levamisole/cocaine-associated ANCA vasculitis, We summarize the clinical presentation, treatment, and outcomes of levamisole induced vasculitis. There is emerging research on pathogenesis relating to neutrophil extracellular traps (NETs). We review studies implicating role of NETs in the pathogenesis of levamisole induced vasculitis. Further research to explore the use of NETs as therapeutic targets in drug induced vasculitis is needed.

1 April 2022 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
SKSam Kant
Sam Kant
AKAndreas Kronbichler
Andreas Kronbichler
PSPurva Sharma
Purva Sharma
DGDuvuru Geetha
Duvuru Geetha

26 January 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
BOBalazs Odler
Balazs Odler
RRRegina Riedl
Regina Riedl
PGPhilipp Gauckler
Philipp Gauckler
Jae Il ShinJae Il Shin
Jae Il Shin
JLJohannes Leierer
Johannes Leierer
Andreas KronbichlerAndreas Kronbichler
Andreas Kronbichler
Objectives Severe infections contribute to morbidity and mortality in antineutrophil cytoplasm antibody-associated vasculitis (AAV). This study aimed to identify risk factors associated with severe infections in participants of the Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis (RAVE) trial. Methods Data on 197 patients recruited into the RAVE trial were analysed. Participants received either rituximab (RTX) or cyclophosphamide (CYC), followed by azathioprine (AZA). Clinical and laboratory data of patients with and without severe infections (≥grade 3, according to the Common Terminology Criteria for Adverse Events version 3.0) were compared. Risk factors for severe infections were investigated using Cox-regression models. Results Eighteen of 22 (82%) severe infections occurred within 6 months after trial entry, most commonly respiratory tract infections (15/22, 68%). At baseline, lower absolute numbers of CD19+ cells were observed in patients with severe infections either receiving RTX or CYC/AZA at baseline, while CD5+B and CD3+T cells did not differ between groups. In Cox-regression analysis, higher baseline serum immunoglobulin M levels were associated with the risk of severe infections, whereby a higher baseline total CD19+B cell number and prophylaxis against Pneumocystis jirovecii with trimethoprim-sulfamethoxazole (TMP/SMX) with decreased risk of severe infections. Use of TMP/SMX was associated with lower risk of severe infections in both groups, receiving either RTX or CYC/AZA. Conclusions The use of low-dose TMP/SMX is associated with reduced risk of severe infections in patients with AAV treated with either RTX or CYC/AZA. Reduced B cell subpopulations at start of treatment might be a useful correlate of reduced immunocompetence.